[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"degenerative-joint-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:degenerative-joint-disease":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,47,78,102],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":30,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100586828","zimmer-biomet-shoulder-arthroplasty-pmcf-study-100586828",false,"NCT06920459","Zimmer Biomet Shoulder Arthroplasty PMCF Study","Zimmer Biomet Shoulder Arthroplasty Long-term Post Market Clinical Follow-up Study","Inclusion Criteria:\n\n* Patient must be 20 years of age or older.\n* Patient must be anatomically and structurally suited to receive shoulder arthroplasty implants.\n* Patient is a candidate for shoulder arthroplasty due to one or more of the following:\n\nNon-inflammatory degenerative joint disease including osteoarthritis and avascular necrosis.\n\nRheumatoid arthritis. Fractures of the proximal humerus, where other methods of treatment are deemed inadequate.\n\nDifficult clinical management problems, where other method of treatment may not be suitable or may be inadequate.\n\n* Patient must be able and willing to complete the protocol required follow-up.\n* Patient must be able and willing to sign the IRB\u002FEC approved informed consent.\n\nExclusion Criteria:\n\n* Patient is unwilling or unable to give consent or to comply with the follow-up program.\n* Patient has any condition which would in the judgement of the Investigator, place the patient at undue risk or interfere with the study.\n* Patient is known to be pregnant or breastfeeding.\n* Patient is a vulnerable subject (prisoner, mentally incompetent or unable to understand what participation to the study entails, a known alcohol or drug abuser, and\u002For anticipated to be non- compliant).\n* Patient is uncooperative or patient with neurologic disorders who is incapable or unwilling to follow directions.\n* Patient has any sign of infection affecting the shoulder joint or in its proximity which may spread to the implant site.\n* Patient has rapid joint destruction, marked bone loss, or bone resorption apparent on roentgenogram.\n* Patient has any neuromuscular disease compromising the affected limb that would render the procedure unjustifiable.\n* Patient presents with osteoporosis, which in the opinion of the Investigator, may limit the subject's ability to support total shoulder arthroplasty using the study device.\n* Patient has a metabolic disorder that may impair bone formation.\n* Patient has osteomalacia.","ALL","20 Years",{"count":19,"type":20},50,"ESTIMATED","OBSERVATIONAL","This is a multicenter, prospective, non-controlled post market surveillance study. The objectives of this study are to confirm the safety, performance, and clinical benefits of the Zimmer Biomet Shoulder Arthroplasty systems in primary anatomic shoulder arthroplasty and its instrumentation. Safety of the systems will be assessed by monitoring the frequency and incidence of adverse events. The performance and clinical benefits will be evaluated by assessment of the overall pain and functional performance, qualify of life, and radiographic parameters of all enrolled study subjects.",[24,25,26,27,28,29],"Shoulder Fractures","Shoulder Arthritis Osteoarthritis","Shoulder Injury","Shoulder Pain","Degenerative Joint Disease","Arthritis Shoulder",[31,32,33],"medical device","PMCF","Anatomic Total Shoulder Arthroplasty","RECRUITING","2026-06-05",{"date":37,"type":38},"2026-06-08","ACTUAL",{"date":40,"type":38},"2025-04-29",{"date":42,"type":20},"2037-06",{"name":44,"class":45},"Zimmer Biomet","INDUSTRY",2,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":16,"minAge":54,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":58,"phases":59,"briefSummary":61,"conditions":62,"keywords":66,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":77},"100466718","safety-and-effectiveness-of-the-hit-reverse-hrs-100466718","NCT05357378","Safety and Effectiveness of the HIT Reverse HRS","Safety and Effectiveness of the Hip Innovation Technology Reverse Hip Replacement System in Primary Total Hip Arthroplasty: A Pivotal Study","Inclusion Criteria:\n\n* Patient requires primary THA due to NIDJD or any of its composite diagnoses such as osteoarthritis, avascular necrosis, posttraumatic arthritis, slipped capital epiphysis, fracture of the pelvis, and diastrophic variant requiring unilateral primary THA.\n* Patient is between 50 (inclusive) and 75 (inclusive) years of age at the time of enrollment.\n* Patient has preoperative medical clearance and is free from or treated for medical conditions that would pose excessive operative risk.\n* Patient has a signed and dated Informed Consent Form (ICF).\n* Patient is willing and able to participate in required follow-up visits at the investigational site and to complete study procedures and questionnaires.\n\nExclusion Criteria:\n\n* Patient has received earlier THA, hemi-arthroplasty, or fusion in the contralateral hip in the last 24 months.\n* Patient has received earlier THA, hemi-arthroplasty, or fusion in the contralateral hip more than 24 months ago and has a contralateral hip-specific pain rating of ≥2 on a Numeric Rating Scale 0-10.\n* Patient needs bilateral hip replacement or has a planned THA on the contralateral hip joint in the next 24 months.\n* Patient needs knee arthroplasty or has a planned total knee arthroplasty in the next 24 months.\n* Patient has a known allergy to titanium and\u002For XLPE.\n* Patient has known metal sensitivities to cobalt chromium (CoCr).\n* Patient has a history of septic arthritis in the index joint.\n* Patient has insufficient acetabular or femoral bone stock in which good anchorage of the implants is unlikely or impossible.\n* Patient has total or partial absence of the muscular or ligamentous apparatus.\n* Patient has known moderate to severe renal insufficiency.\n* Patient has vascular insufficiency, muscular atrophy, or neuromuscular disease in either leg (based on the Investigator's judgment).\n* Patient has a deformity of the affected limb or significant anatomic variance of the affected hip.\n* Patient has an active malignancy or history of invasive malignancy within the last 5 years, except for superficial basal cell carcinoma or squamous cell carcinoma of the skin that has been definitively treated. Patients with carcinoma in situ of the uterine cervix definitively treated more than 1 year prior to enrollment may enter the study.\n* Patient has Paget's disease, Charcot-Marie-Tooth disease, or osteomalacia.\n* Patient has an inflammatory DJD including any of its composite diagnoses: rheumatoid arthritis, systemic lupus erythematosus, pigmented villonodular synovitis, juvenile rheumatoid arthritis, and other arthritic processes of inflammatory or autoimmune etiology.\n* Patient has any condition that would interfere with self-assessment of pain, function, or quality of life (QoL) required for patient-reported outcomes during the study (based on the Investigator's judgment).\n* Patient has a Body Mass Index (BMI) of 40 or higher.\n* Patient has an active infection (e.g., hepatitis, Acquired Immune Deficiency Syndrome (AIDS), AIDS-related Complex (ARC)) that is systemic or at the site of the intended surgery.\n* Patient is currently participating in any investigational study not related to this study's preoperative or postoperative care.\n* Patient is currently pregnant or is planning to become pregnant during the study.\n* Patient is a competitive or professional athlete.","50 Years","75 Years",{"count":57,"type":20},288,"INTERVENTIONAL",[60],"NA","The purpose of this study is to determine if the use of the HIT Reverse Hip Replacement System is safe and effective in patients undergoing total hip replacement. We will determine whether it is safe and effective by comparing it to the control devices.",[28,63,64,65],"Osteoarthritis, Hip","Avascular Necrosis of Hip","Traumatic Arthropathy-Hip",[67],"total hip arthroplasty","2026-05-07",{"date":70,"type":38},"2026-05-11",{"date":72,"type":38},"2022-07-15",{"date":74,"type":20},"2035-07-15",{"name":76,"class":45},"Hip Innovation Technology",6,{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":4,"eligibilityCriteria":84,"healthyVolunteers":11,"sex":16,"minAge":85,"maxAge":4,"enrollmentInfo":86,"targetDuration":4,"studyType":58,"phases":88,"briefSummary":89,"conditions":90,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":101},"100555020","hyaluronic-acid-and-adelmidrol-hyadrol-in-patients-with-degenerative-joint-disease-100555020","NCT06506656","Hyaluronic Acid and Adelmidrol (Hyadrol®) in Patients With Degenerative Joint Disease","Effect of an Intra-articular Treatment With a Combination of Hyaluronic Acid and Adelmidrol (Hyadrol®) on Pain, Joint Stiffness and Functional Limitation in Patients With Degenerative Joint Disease","Inclusion Criteria:\n\n* age ≥ 40 years;\n* both genders;\n* diagnosis of stage II-III coxarthrosis or rhizoarthrosis according to radiological classification (Kellgren and Lawrence or modified Eaton-Littler criteria respectively)\n* pain intensity ≥ 5 on NRS;\n* wash-out for at least two weeks from anti-inflammatory drugs before enrollment;\n* compliant patients;\n* signed informed consent.\n\nExclusion Criteria:\n\n* age \\\u003C 40 years;\n* presence of concomitant inflammatory systemic pathologies (e.g.: rheumatoid arthritis, etc.);\n* severe and progressive clinical conditions,\n* NSAIDs therapy in the 2 weeks prior to enrollment;\n* corticosteroid therapy in the 3 months prior to enrollment;\n* chondroprotectors intake in the 6 months prior to enrollment;\n* arthroscopic procedures or intra-articular visco-supplementation in the 6 months prior to enrollment;\n* presence of cognitive impairment;\n* ongoing rehabilitation and\u002For physiotherapy;\n* allergy or hypersensitivity to the study treatment;\n* pregnant and\u002For lactating female subjects;\n* not compliant patients;\n* denied informed consent.","40 Years",{"count":87,"type":20},59,[60],"Osteoarthritis is a major cause of chronic musculoskeletal pain. Behind this disorder there is a process of chronic neuroinflammation due to the overactivation of mast cells at the tissue level. The mast cells present in the synovial membranes act as first sensors in pathological situations, degranulating in an uncontrolled manner.\n\nFurthermore, in degenerative joint pathologies, there is a marked reduction in the viscoelastic capacity of the synovial fluid associated with a reduction in both the concentration and the average molecular weight of endogenous hyaluronic acid. The association of hyaluronic acid and Adelmidrol (Hyadrol®) could represent an effective treatment for controlling the neuroinflammation process that supports degenerative joint diseases.\n\nThe objective of the present clinical investigation is to evaluate its safety and efficacy in patients with arthritis of the hip (coxarthrosis) and trapezium-metacarpal joints (rhizoarthrosis).",[28],"2024-07-17",{"date":93,"type":38},"2024-07-18",{"date":95,"type":38},"2024-07-16",{"date":97,"type":20},"2025-07",{"name":99,"class":100},"University of Roma La Sapienza","OTHER",1,{"id":103,"slug":104,"hasResults":11,"nctId":105,"briefTitle":106,"officialTitle":107,"acronym":4,"eligibilityCriteria":108,"healthyVolunteers":109,"sex":16,"minAge":85,"maxAge":55,"enrollmentInfo":110,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":112,"conditions":113,"keywords":4,"overallStatus":116,"whyStopped":4,"lastUpdateSubmitDate":117,"lastUpdatePostDateStruct":118,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":4},"100433020","prospective-post-market-study-examining-the-effectiveness-of-the-ecofit-100433020","NCT04918680","Prospective Post-market Study Examining the Effectiveness of the EcoFit®","Prospective Post-market Study Examining the Effectiveness of the EcoFit® Total Hip System With Implacross® E Polyethylene","Inclusion Criteria:\n\n* Subject must be a candidate for a total primary hip replacement.\n* Subject must have degenerative joint disease, including osteoarthritis or traumatic arthritis, OR a femoral fracture which can be treated by a primary hip replacement and no other hardware\n* Subject has a BMI of 40.00 kg\u002Fm2 or less at the time of enrollment\n* Subject is likely to be available for evaluation for the duration of the study\n* Subject is able and willing to sign the informed consent and follow study procedures\n* Subject is not pregnant\n\nExclusion Criteria:\n\n* Subject has had a prior hip replacement in the subject hip\n* Subject has an active cancer or is a survivor for \\\u003C5 years except for squamous cell or basal cell skin cancer\n* Subject has a chronic disease(s) where, in the opinion of the investigator, the disease will interfere with the patient's ability to follow the protocol\n* Subject is currently a documented substance abuser (alcohol or other addictions)\n* Subject has an infection, or history of infection (within the last 3 months), acute or chronic, local or systemic\n* Subject has a history of muscular, neurological or vascular deficiencies which compromise the affected extremity\n* Subject has a BMI \\> 40.00 kg\u002Fm2\n* Subject has a mental condition that may interfere with the subject's ability to give an informed consent or willingness to fulfill the study requirements (i.e., severe mental retardation such that the Subject cannot understand the informed consent process, global dementia, prior strokes that interfere with the Subject's cognitive abilities, senile dementia, and Alzheimer's Disease)\n* Subject is a prisoner\n* Subject is pregnant\n* Subject has known materials sensitivity (to metals)",true,{"count":111,"type":20},500,"The purpose of this study is to evaluate the safety and effectiveness of the EcoFit Hip with implacross E polyethylene for total hip replacement surgery.",[28,114,63,115],"Femoral Fracture","Traumatic Arthritis","NOT_YET_RECRUITING","2021-06-01",{"date":119,"type":38},"2021-06-09",{"date":121,"type":20},"2021-06-21",{"date":123,"type":20},"2027-03-30",{"name":125,"class":45},"Implantcast North America, LLC"]